The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CD38 Monoclonal Antibody Drugs Market Research Report 2025
Synopsis
The global CD38 Monoclonal Antibody Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CD38 Monoclonal Antibody Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD38 Monoclonal Antibody Drugs.
Report Scope
The CD38 Monoclonal Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (KG) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CD38 Monoclonal Antibody Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CD38 Monoclonal Antibody Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson
Sanofi
Takeda Pharmaceutical Company
CASI Pharmaceutical Company
Mab Biopharma
Segment by Type
Daretuzumab
Isartuximab
Engineered Toxin Body
Segment by Application
Multiple Myeloma
Diffuse Large B Cell Lymphoma
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of CD38 Monoclonal Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of CD38 Monoclonal Antibody Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global CD38 Monoclonal Antibody Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CD38 Monoclonal Antibody Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD38 Monoclonal Antibody Drugs.
Report Scope
The CD38 Monoclonal Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (KG) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CD38 Monoclonal Antibody Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CD38 Monoclonal Antibody Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson
Sanofi
Takeda Pharmaceutical Company
CASI Pharmaceutical Company
Mab Biopharma
Segment by Type
Daretuzumab
Isartuximab
Engineered Toxin Body
Segment by Application
Multiple Myeloma
Diffuse Large B Cell Lymphoma
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of CD38 Monoclonal Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of CD38 Monoclonal Antibody Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 CD38 Monoclonal Antibody Drugs Market Overview
1.1 Product Overview and Scope of CD38 Monoclonal Antibody Drugs
1.2 CD38 Monoclonal Antibody Drugs Segment by Type
1.2.1 Global CD38 Monoclonal Antibody Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Daretuzumab
1.2.3 Isartuximab
1.2.4 Engineered Toxin Body
1.3 CD38 Monoclonal Antibody Drugs Segment by Application
1.3.1 Global CD38 Monoclonal Antibody Drugs Market Value by Application: (2024-2030)
1.3.2 Multiple Myeloma
1.3.3 Diffuse Large B Cell Lymphoma
1.3.4 Other
1.4 Global CD38 Monoclonal Antibody Drugs Market Size Estimates and Forecasts
1.4.1 Global CD38 Monoclonal Antibody Drugs Revenue 2019-2030
1.4.2 Global CD38 Monoclonal Antibody Drugs Sales 2019-2030
1.4.3 Global CD38 Monoclonal Antibody Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 CD38 Monoclonal Antibody Drugs Market Competition by Manufacturers
2.1 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global CD38 Monoclonal Antibody Drugs Average Price by Manufacturers (2019-2024)
2.4 Global CD38 Monoclonal Antibody Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of CD38 Monoclonal Antibody Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of CD38 Monoclonal Antibody Drugs, Product Type & Application
2.7 CD38 Monoclonal Antibody Drugs Market Competitive Situation and Trends
2.7.1 CD38 Monoclonal Antibody Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest CD38 Monoclonal Antibody Drugs Players Market Share by Revenue
2.7.3 Global CD38 Monoclonal Antibody Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 CD38 Monoclonal Antibody Drugs Retrospective Market Scenario by Region
3.1 Global CD38 Monoclonal Antibody Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global CD38 Monoclonal Antibody Drugs Global CD38 Monoclonal Antibody Drugs Sales by Region: 2019-2030
3.2.1 Global CD38 Monoclonal Antibody Drugs Sales by Region: 2019-2024
3.2.2 Global CD38 Monoclonal Antibody Drugs Sales by Region: 2025-2030
3.3 Global CD38 Monoclonal Antibody Drugs Global CD38 Monoclonal Antibody Drugs Revenue by Region: 2019-2030
3.3.1 Global CD38 Monoclonal Antibody Drugs Revenue by Region: 2019-2024
3.3.2 Global CD38 Monoclonal Antibody Drugs Revenue by Region: 2025-2030
3.4 North America CD38 Monoclonal Antibody Drugs Market Facts & Figures by Country
3.4.1 North America CD38 Monoclonal Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America CD38 Monoclonal Antibody Drugs Sales by Country (2019-2030)
3.4.3 North America CD38 Monoclonal Antibody Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe CD38 Monoclonal Antibody Drugs Market Facts & Figures by Country
3.5.1 Europe CD38 Monoclonal Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe CD38 Monoclonal Antibody Drugs Sales by Country (2019-2030)
3.5.3 Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific CD38 Monoclonal Antibody Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific CD38 Monoclonal Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific CD38 Monoclonal Antibody Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific CD38 Monoclonal Antibody Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America CD38 Monoclonal Antibody Drugs Market Facts & Figures by Country
3.7.1 Latin America CD38 Monoclonal Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America CD38 Monoclonal Antibody Drugs Sales by Country (2019-2030)
3.7.3 Latin America CD38 Monoclonal Antibody Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa CD38 Monoclonal Antibody Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa CD38 Monoclonal Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa CD38 Monoclonal Antibody Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global CD38 Monoclonal Antibody Drugs Sales by Type (2019-2030)
4.1.1 Global CD38 Monoclonal Antibody Drugs Sales by Type (2019-2024)
4.1.2 Global CD38 Monoclonal Antibody Drugs Sales by Type (2025-2030)
4.1.3 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2019-2030)
4.2 Global CD38 Monoclonal Antibody Drugs Revenue by Type (2019-2030)
4.2.1 Global CD38 Monoclonal Antibody Drugs Revenue by Type (2019-2024)
4.2.2 Global CD38 Monoclonal Antibody Drugs Revenue by Type (2025-2030)
4.2.3 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2019-2030)
4.3 Global CD38 Monoclonal Antibody Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global CD38 Monoclonal Antibody Drugs Sales by Application (2019-2030)
5.1.1 Global CD38 Monoclonal Antibody Drugs Sales by Application (2019-2024)
5.1.2 Global CD38 Monoclonal Antibody Drugs Sales by Application (2025-2030)
5.1.3 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2019-2030)
5.2 Global CD38 Monoclonal Antibody Drugs Revenue by Application (2019-2030)
5.2.1 Global CD38 Monoclonal Antibody Drugs Revenue by Application (2019-2024)
5.2.2 Global CD38 Monoclonal Antibody Drugs Revenue by Application (2025-2030)
5.2.3 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application (2019-2030)
5.3 Global CD38 Monoclonal Antibody Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Johnson
6.1.1 Johnson Corporation Information
6.1.2 Johnson Description and Business Overview
6.1.3 Johnson CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Johnson CD38 Monoclonal Antibody Drugs Product Portfolio
6.1.5 Johnson Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi CD38 Monoclonal Antibody Drugs Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Takeda Pharmaceutical Company
6.3.1 Takeda Pharmaceutical Company Corporation Information
6.3.2 Takeda Pharmaceutical Company Description and Business Overview
6.3.3 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolio
6.3.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.4 CASI Pharmaceutical Company
6.4.1 CASI Pharmaceutical Company Corporation Information
6.4.2 CASI Pharmaceutical Company Description and Business Overview
6.4.3 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolio
6.4.5 CASI Pharmaceutical Company Recent Developments/Updates
6.5 Mab Biopharma
6.5.1 Mab Biopharma Corporation Information
6.5.2 Mab Biopharma Description and Business Overview
6.5.3 Mab Biopharma CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Mab Biopharma CD38 Monoclonal Antibody Drugs Product Portfolio
6.5.5 Mab Biopharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 CD38 Monoclonal Antibody Drugs Industry Chain Analysis
7.2 CD38 Monoclonal Antibody Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 CD38 Monoclonal Antibody Drugs Production Mode & Process
7.4 CD38 Monoclonal Antibody Drugs Sales and Marketing
7.4.1 CD38 Monoclonal Antibody Drugs Sales Channels
7.4.2 CD38 Monoclonal Antibody Drugs Distributors
7.5 CD38 Monoclonal Antibody Drugs Customers
8 CD38 Monoclonal Antibody Drugs Market Dynamics
8.1 CD38 Monoclonal Antibody Drugs Industry Trends
8.2 CD38 Monoclonal Antibody Drugs Market Drivers
8.3 CD38 Monoclonal Antibody Drugs Market Challenges
8.4 CD38 Monoclonal Antibody Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global CD38 Monoclonal Antibody Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global CD38 Monoclonal Antibody Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global CD38 Monoclonal Antibody Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global CD38 Monoclonal Antibody Drugs Sales (KG) of Key Manufacturers (2019-2024)
Table 5. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global CD38 Monoclonal Antibody Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global CD38 Monoclonal Antibody Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market CD38 Monoclonal Antibody Drugs Average Price (US$/g) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of CD38 Monoclonal Antibody Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of CD38 Monoclonal Antibody Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of CD38 Monoclonal Antibody Drugs, Product Type & Application
Table 12. Global Key Manufacturers of CD38 Monoclonal Antibody Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global CD38 Monoclonal Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD38 Monoclonal Antibody Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global CD38 Monoclonal Antibody Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global CD38 Monoclonal Antibody Drugs Sales by Region (2019-2024) & (KG)
Table 18. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2019-2024)
Table 19. Global CD38 Monoclonal Antibody Drugs Sales by Region (2025-2030) & (KG)
Table 20. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2025-2030)
Table 21. Global CD38 Monoclonal Antibody Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global CD38 Monoclonal Antibody Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America CD38 Monoclonal Antibody Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America CD38 Monoclonal Antibody Drugs Sales by Country (2019-2024) & (KG)
Table 27. North America CD38 Monoclonal Antibody Drugs Sales by Country (2025-2030) & (KG)
Table 28. North America CD38 Monoclonal Antibody Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America CD38 Monoclonal Antibody Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe CD38 Monoclonal Antibody Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe CD38 Monoclonal Antibody Drugs Sales by Country (2019-2024) & (KG)
Table 32. Europe CD38 Monoclonal Antibody Drugs Sales by Country (2025-2030) & (KG)
Table 33. Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific CD38 Monoclonal Antibody Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific CD38 Monoclonal Antibody Drugs Sales by Region (2019-2024) & (KG)
Table 37. Asia Pacific CD38 Monoclonal Antibody Drugs Sales by Region (2025-2030) & (KG)
Table 38. Asia Pacific CD38 Monoclonal Antibody Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific CD38 Monoclonal Antibody Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America CD38 Monoclonal Antibody Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America CD38 Monoclonal Antibody Drugs Sales by Country (2019-2024) & (KG)
Table 42. Latin America CD38 Monoclonal Antibody Drugs Sales by Country (2025-2030) & (KG)
Table 43. Latin America CD38 Monoclonal Antibody Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America CD38 Monoclonal Antibody Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Country (2019-2024) & (KG)
Table 47. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Country (2025-2030) & (KG)
Table 48. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global CD38 Monoclonal Antibody Drugs Sales (KG) by Type (2019-2024)
Table 51. Global CD38 Monoclonal Antibody Drugs Sales (KG) by Type (2025-2030)
Table 52. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2019-2024)
Table 53. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2025-2030)
Table 54. Global CD38 Monoclonal Antibody Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global CD38 Monoclonal Antibody Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global CD38 Monoclonal Antibody Drugs Price (US$/g) by Type (2019-2024)
Table 59. Global CD38 Monoclonal Antibody Drugs Price (US$/g) by Type (2025-2030)
Table 60. Global CD38 Monoclonal Antibody Drugs Sales (KG) by Application (2019-2024)
Table 61. Global CD38 Monoclonal Antibody Drugs Sales (KG) by Application (2025-2030)
Table 62. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2019-2024)
Table 63. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2025-2030)
Table 64. Global CD38 Monoclonal Antibody Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global CD38 Monoclonal Antibody Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global CD38 Monoclonal Antibody Drugs Price (US$/g) by Application (2019-2024)
Table 69. Global CD38 Monoclonal Antibody Drugs Price (US$/g) by Application (2025-2030)
Table 70. Johnson Corporation Information
Table 71. Johnson Description and Business Overview
Table 72. Johnson CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 73. Johnson CD38 Monoclonal Antibody Drugs Product
Table 74. Johnson Recent Developments/Updates
Table 75. Sanofi Corporation Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 78. Sanofi CD38 Monoclonal Antibody Drugs Product
Table 79. Sanofi Recent Developments/Updates
Table 80. Takeda Pharmaceutical Company Corporation Information
Table 81. Takeda Pharmaceutical Company Description and Business Overview
Table 82. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 83. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product
Table 84. Takeda Pharmaceutical Company Recent Developments/Updates
Table 85. CASI Pharmaceutical Company Corporation Information
Table 86. CASI Pharmaceutical Company Description and Business Overview
Table 87. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 88. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product
Table 89. CASI Pharmaceutical Company Recent Developments/Updates
Table 90. Mab Biopharma Corporation Information
Table 91. Mab Biopharma Description and Business Overview
Table 92. Mab Biopharma CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 93. Mab Biopharma CD38 Monoclonal Antibody Drugs Product
Table 94. Mab Biopharma Recent Developments/Updates
Table 95. Key Raw Materials Lists
Table 96. Raw Materials Key Suppliers Lists
Table 97. CD38 Monoclonal Antibody Drugs Distributors List
Table 98. CD38 Monoclonal Antibody Drugs Customers List
Table 99. CD38 Monoclonal Antibody Drugs Market Trends
Table 100. CD38 Monoclonal Antibody Drugs Market Drivers
Table 101. CD38 Monoclonal Antibody Drugs Market Challenges
Table 102. CD38 Monoclonal Antibody Drugs Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of CD38 Monoclonal Antibody Drugs
Figure 2. Global CD38 Monoclonal Antibody Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global CD38 Monoclonal Antibody Drugs Market Share by Type in 2023 & 2030
Figure 4. Daretuzumab Product Picture
Figure 5. Isartuximab Product Picture
Figure 6. Engineered Toxin Body Product Picture
Figure 7. Global CD38 Monoclonal Antibody Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global CD38 Monoclonal Antibody Drugs Market Share by Application in 2023 & 2030
Figure 9. Multiple Myeloma
Figure 10. Diffuse Large B Cell Lymphoma
Figure 11. Other
Figure 12. Global CD38 Monoclonal Antibody Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global CD38 Monoclonal Antibody Drugs Market Size (2019-2030) & (US$ Million)
Figure 14. Global CD38 Monoclonal Antibody Drugs Sales (2019-2030) & (KG)
Figure 15. Global CD38 Monoclonal Antibody Drugs Average Price (US$/g) & (2019-2030)
Figure 16. CD38 Monoclonal Antibody Drugs Report Years Considered
Figure 17. CD38 Monoclonal Antibody Drugs Sales Share by Manufacturers in 2023
Figure 18. Global CD38 Monoclonal Antibody Drugs Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest CD38 Monoclonal Antibody Drugs Players: Market Share by Revenue in 2023
Figure 20. CD38 Monoclonal Antibody Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global CD38 Monoclonal Antibody Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2019-2030)
Figure 23. North America CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2019-2030)
Figure 24. United States CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2019-2030)
Figure 27. Europe CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2019-2030)
Figure 28. Germany CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2019-2030)
Figure 35. China CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2019-2030)
Figure 45. Latin America CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2019-2030)
Figure 46. Mexico CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2019-2030)
Figure 51. Turkey CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE CD38 Monoclonal Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of CD38 Monoclonal Antibody Drugs by Type (2019-2030)
Figure 55. Global Revenue Market Share of CD38 Monoclonal Antibody Drugs by Type (2019-2030)
Figure 56. Global CD38 Monoclonal Antibody Drugs Price (US$/g) by Type (2019-2030)
Figure 57. Global Sales Market Share of CD38 Monoclonal Antibody Drugs by Application (2019-2030)
Figure 58. Global Revenue Market Share of CD38 Monoclonal Antibody Drugs by Application (2019-2030)
Figure 59. Global CD38 Monoclonal Antibody Drugs Price (US$/g) by Application (2019-2030)
Figure 60. CD38 Monoclonal Antibody Drugs Value Chain
Figure 61. CD38 Monoclonal Antibody Drugs Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
